- Home
- NSRX vs DXR Comparison
NSRX vs DXR Comparison
Compare NSRX & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NSRX | DXR |
|---|---|---|
| Founded | 2019 | 1970 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.4M | 61.5M |
| IPO Year | 2025 | N/A |
Fundamental Metrics
Financial Performance| Metric | NSRX | DXR |
|---|---|---|
| Price | $6.80 | $12.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $22.00 | ★ $25.00 |
| AVG Volume (30 Days) | 2.8K | ★ 4.3K |
| Earning Date | 12-26-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.46 |
| EPS | N/A | ★ 0.36 |
| Revenue | N/A | ★ $66,306.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $33.97 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.90 | $6.55 |
| 52 Week High | $9.99 | $14.15 |
Technical Indicators
Market Signals| Indicator | NSRX | DXR |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 40.20 |
| Support Level | N/A | $12.11 |
| Resistance Level | N/A | $13.02 |
| Average True Range (ATR) | 0.00 | 0.47 |
| MACD | 0.00 | -0.09 |
| Stochastic Oscillator | 0.00 | 6.75 |
Price Performance
Historical ComparisonAbout NSRX Nasus Pharma Ltd. Ordinary Shares
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.